Enanta Pharmaceuticals Correlations

ENTA Stock

USD 9.34 0.03 0.32%

The current 90-days correlation between Enanta Pharmaceuticals and Design Therapeutics is 0.26 (i.e., Modest diversification). The correlation of Enanta Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Enanta Pharmaceuticals Correlation With Market

Modest diversification

The correlation between Enanta Pharmaceuticals and DJI is 0.26 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Enanta Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

Moving together with Enanta Stock

0.65	EQ	Equillium	Pair Corr
0.79	VALN	Valneva SE ADR	Pair Corr
0.72	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.62	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.68	IPSC	Century Therapeutics	Pair Corr
0.65	NKTX	Nkarta Inc	Pair Corr
0.62	AGL	agilon health	Pair Corr
0.76	BACK	IMAC Holdings	Pair Corr
0.63	TCHH	Trustcash Holdings	Pair Corr

Moving against Enanta Stock

0.56	RNXT	RenovoRx	Pair Corr
0.42	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.7	T	ATT Inc Aggressive Push	Pair Corr
0.67	INTC	Intel Fiscal Year End 23rd of January 2025	Pair Corr
0.58	CVX	Chevron Corp Fiscal Year End 7th of February 2025	Pair Corr
0.55	HD	Home Depot	Pair Corr
0.54	BAC	Bank of America Fiscal Year End 10th of January 2025	Pair Corr
0.54	AA	Alcoa Corp Fiscal Year End 15th of January 2025	Pair Corr
0.48	CAT	Caterpillar Fiscal Year End 3rd of February 2025	Pair Corr
0.42	HPQ	HP Inc	Pair Corr
0.4	JPM	JPMorgan Chase Fiscal Year End 10th of January 2025	Pair Corr
0.35	VFS	VinFast Auto Earnings Call Tomorrow	Pair Corr

Related Correlations Analysis

	GLUE	DSGN	HOWL	IKNA	STOK	CRNX	INBX	MRUS	LYEL	KRON
GLUE		0.5	0.03	0.24	0.0	0.53	-0.02	-0.1	-0.27	-0.43	GLUE
DSGN	0.5		0.12	0.25	0.06	0.58	0.28	-0.07	-0.16	-0.55	DSGN
HOWL	0.03	0.12		0.12	0.04	0.39	0.23	0.49	-0.08	0.2	HOWL
IKNA	0.24	0.25	0.12		-0.03	0.23	-0.16	0.29	0.17	0.0	IKNA
STOK	0.0	0.06	0.04	-0.03		-0.18	0.26	0.22	0.46	0.24	STOK
CRNX	0.53	0.58	0.39	0.23	-0.18		0.14	0.3	-0.38	-0.47	CRNX
INBX	-0.02	0.28	0.23	-0.16	0.26	0.14		0.3	-0.02	0.08	INBX
MRUS	-0.1	-0.07	0.49	0.29	0.22	0.3	0.3		0.12	0.31	MRUS
LYEL	-0.27	-0.16	-0.08	0.17	0.46	-0.38	-0.02	0.12		0.44	LYEL
KRON	-0.43	-0.55	0.2	0.0	0.24	-0.47	0.08	0.31	0.44		KRON
	GLUE	DSGN	HOWL	IKNA	STOK	CRNX	INBX	MRUS	LYEL	KRON

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

CRNX	+ 0.58	DSGN
CRNX	+ 0.53	GLUE
DSGN	+ 0.5	GLUE
MRUS	+ 0.49	HOWL
LYEL	+ 0.46	STOK
KRON	+ 0.44	LYEL

High negative correlations

KRON	- 0.55	DSGN
KRON	- 0.47	CRNX
KRON	- 0.43	GLUE
LYEL	- 0.38	CRNX
LYEL	- 0.27	GLUE
CRNX	- 0.18	STOK

Risk-Adjusted Indicators

There is a big difference between Enanta Stock performing well and Enanta Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Enanta Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
GLUE	5.33	0.74	0.22	0.34	3.86	(7.30)	10.11	(8.18)	102.66
DSGN	4.07	0.07	0.04	0.15	5.31	(4.43)	9.61	(8.21)	35.31
HOWL	4.99	(0.24)	(0.02)	0.02	4.85	(7.90)	9.21	(8.75)	49.02
IKNA	1.09	(0.07)	(0.07)	(0.01)	1.39	(1.50)	1.81	(1.74)	13.50
STOK	2.63	(0.38)	0.00	(0.17)	0.00	0.00	4.68	(6.99)	21.35
CRNX	1.71	(0.01)	(0.01)	0.11	2.43	(1.68)	3.67	(3.45)	16.75
INBX	2.27	0.08	0.01	0.25	2.71	(2.75)	4.92	(6.11)	16.80
MRUS	1.67	(0.37)	0.00	(0.20)	0.00	0.00	3.08	(2.83)	10.85
LYEL	4.99	(0.88)	0.00	(0.10)	0.00	0.00	13.39	(9.47)	36.92
KRON	2.48	(0.13)	0.00	(0.21)	0.00	0.00	5.56	(6.25)	16.20

Enanta Pharmaceuticals Corporate Management

Nathaniel JD	General VP	Profile
Scott MD	Senior Officer	Profile
Nathalie MD	Consultant	Profile
Jennifer Viera	Senior Communications	Profile
Tara Kieffer	Senior Development	Profile
Brendan Luu	Senior Development	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC